Physicians Realty Trust, a self-managed healthcare real estate company, focuses on the acquisition, development, ownership, and management of healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. The company has market cap of $3.33 billion. The companyÂ’s portfolio would consists of 19 medical office buildings with approximately 528,048 net leasable square feet located in 10 states. It has a 77.09 P/E ratio. It intends to elect and qualify to be taxed as a real estate investment trust for federal income tax purposes.
Deerfield Management Company increased Biocryst Pharmaceuticals (BCRX) stake by 13.42% reported in 2017Q2 SEC filing. Deerfield Management Company acquired 413,966 shares as Biocryst Pharmaceuticals (BCRX)’s stock declined 16.46%. The Deerfield Management Company holds 3.50M shares with $19.46M value, up from 3.09M last quarter. Biocryst Pharmaceuticals now has $493.99 million valuation. The stock decreased 3.65% or $0.19 during the last trading session, reaching $5.02. About 1.11M shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since December 12, 2016 and is uptrending. It has outperformed by 58.38% the S&P500.
Among 13 analysts covering BioCryst Pharmaceuticals (NASDAQ:BCRX), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. BioCryst Pharmaceuticals had 31 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Tuesday, February 9. Needham downgraded the stock to “Hold” rating in Tuesday, February 9 report. The rating was downgraded by JMP Securities to “Market Perform” on Thursday, August 4. The firm has “Overweight” rating by JP Morgan given on Wednesday, September 6. The firm has “Buy” rating by Jefferies given on Wednesday, January 6. Noble Financial maintained the stock with “Buy” rating in Friday, May 26 report. The stock has “Hold” rating by RBC Capital Markets on Thursday, November 2. The firm earned “Neutral” rating on Tuesday, February 9 by JP Morgan. The rating was upgraded by Piperjaffray to “Overweight” on Friday, August 12. The firm has “Buy” rating by JMP Securities given on Tuesday, November 28.
Deerfield Management Company decreased Lannet Inc (NYSE:LCI) stake by 329,939 shares to 1.52 million valued at $31.09 million in 2017Q2. It also reduced Dbv Technologies S A stake by 1.08M shares and now owns 665,197 shares. Ehealth Inc (NASDAQ:EHTH) was reduced too.
Investors sentiment increased to 1.69 in Q2 2017. Its up 0.01, from 1.68 in 2017Q1. It is positive, as 15 investors sold BCRX shares while 19 reduced holdings. 18 funds opened positions while 39 raised stakes. 66.24 million shares or 8.58% more from 61.01 million shares in 2017Q1 were reported. Rhumbline Advisers owns 94,303 shares for 0% of their portfolio. Metropolitan Life Insur Ny invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). 12,019 were accumulated by Arrowmark Colorado Holdg Ltd Company. Great West Life Assurance Can has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Eventide Asset Mngmt Ltd Liability Co invested in 0.1% or 290,000 shares. Envestnet Asset Mgmt Incorporated holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 119 shares. Alps owns 72,591 shares. Ra Cap Mngmt Limited Liability Co has 3.29% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Creative Planning has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Vanguard reported 6.01 million shares stake. Barclays Public Limited Company has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Financial Architects holds 0% or 30 shares. New York-based State Common Retirement Fund has invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Royal Savings Bank Of Canada holds 461 shares. Moreover, Nationwide Fund Advsr has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 46,149 shares.
Analysts await Physicians Realty Trust (NYSE:DOC) to report earnings on February, 23. They expect $0.28 earnings per share, up 3.70% or $0.01 from last year’s $0.27 per share. DOC’s profit will be $51.69 million for 16.11 P/E if the $0.28 EPS becomes a reality. After $0.26 actual earnings per share reported by Physicians Realty Trust for the previous quarter, Wall Street now forecasts 7.69% EPS growth.
Heitman Real Estate Securities Llc holds 2.18% of its portfolio in Physicians Realty Trust for 1.73 million shares. Silvercrest Asset Management Group Llc owns 3.84 million shares or 0.82% of their US portfolio. Moreover, Sit Investment Associates Inc has 0.7% invested in the company for 1.40 million shares. The Washington-based Rainier Investment Management Llc has invested 0.68% in the stock. Pax World Management Llc, a New Hampshire-based fund reported 562,148 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.